Udvalget besluttede, at fordelene ved Elaprase var større end risiciene ved langtidsbehandling af patienter med Hunter syndrom, og anbefalede udstedelse af markedsføringstilladelse for Elaprase.
They decided that the benefits of Elaprase are greater than its risks in the long-term treatment of patients with Hunter syndrome and recommended that Elaprase be given marketing authorisation.